Selected research
Industry Research
Urinary Drugs Industry Research Report 2026
Market perspective
The global Urinary Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Urinary Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Urinary Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Urinary Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Urinary Drugs include Sanofi S.A., Pfizer Inc., GlaxosmithKline Plc., Bayer AG, Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Company Limited, Astellas Pharma Inc. and Allergan Plc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Urinary Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (k tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Urinary Drugs Market by Company
Sanofi S.A.
Pfizer Inc.
GlaxosmithKline Plc.
Bayer AG
Otsuka Pharmaceutical Co., Ltd.
Daiichi Sankyo Company Limited
Astellas Pharma Inc.
Allergan Plc.
Urinary Drugs Segment by Type
Oral
Injectables
Urinary Drugs Segment by Application
Clinic
Hospital
Home Care
Urinary Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Urinary Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Urinary Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Urinary Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Urinary Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Urinary Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Urinary Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Injectables
Applications
- Clinic
- Hospital
- Home Care
Companies covered
- Sanofi S.A.
- Pfizer Inc.
- GlaxosmithKline Plc.
- Bayer AG
- Otsuka Pharmaceutical Co., Ltd.
- Daiichi Sankyo Company Limited
- Astellas Pharma Inc.
- Allergan Plc.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Urinary Drugs Market Size (2021-2032)
- 2.2.2 Global Urinary Drugs Sales (2021-2032)
- 2.2.3 Global Urinary Drugs Market Average Price (2021-2032)
- 2.3 Urinary Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Oral
- 2.3.3 Injectables
- 2.4 Urinary Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Clinic
- 2.4.3 Hospital
- 2.4.4 Home Care
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Urinary Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Urinary Drugs Sales (k tons) of Manufacturers (2021-2026)
- 3.3 Global Urinary Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Urinary Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Urinary Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Urinary Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Urinary Drugs, Product Type & Application
- 3.8 Global Manufacturers of Urinary Drugs, Established Date
- 3.9 Global Urinary Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sanofi S.A.
- 4.1.1 Sanofi S.A. Company Information
- 4.1.2 Sanofi S.A. Business Overview
- 4.1.3 Sanofi S.A. Urinary Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sanofi S.A. Urinary Drugs Product Portfolio
- 4.1.5 Sanofi S.A. Recent Developments
- 4.2 Pfizer Inc.
- 4.2.1 Pfizer Inc. Company Information
- 4.2.2 Pfizer Inc. Business Overview
- 4.2.3 Pfizer Inc. Urinary Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Pfizer Inc. Urinary Drugs Product Portfolio
- 4.2.5 Pfizer Inc. Recent Developments
- 4.3 GlaxosmithKline Plc.
- 4.3.1 GlaxosmithKline Plc. Company Information
- 4.3.2 GlaxosmithKline Plc. Business Overview
- 4.3.3 GlaxosmithKline Plc. Urinary Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 GlaxosmithKline Plc. Urinary Drugs Product Portfolio
- 4.3.5 GlaxosmithKline Plc. Recent Developments
- 4.4 Bayer AG
- 4.4.1 Bayer AG Company Information
- 4.4.2 Bayer AG Business Overview
- 4.4.3 Bayer AG Urinary Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Bayer AG Urinary Drugs Product Portfolio
- 4.4.5 Bayer AG Recent Developments
- 4.5 Otsuka Pharmaceutical Co., Ltd.
- 4.5.1 Otsuka Pharmaceutical Co., Ltd. Company Information
- 4.5.2 Otsuka Pharmaceutical Co., Ltd. Business Overview
- 4.5.3 Otsuka Pharmaceutical Co., Ltd. Urinary Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Otsuka Pharmaceutical Co., Ltd. Urinary Drugs Product Portfolio
- 4.5.5 Otsuka Pharmaceutical Co., Ltd. Recent Developments
- 4.6 Daiichi Sankyo Company Limited
- 4.6.1 Daiichi Sankyo Company Limited Company Information
- 4.6.2 Daiichi Sankyo Company Limited Business Overview
- 4.6.3 Daiichi Sankyo Company Limited Urinary Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Daiichi Sankyo Company Limited Urinary Drugs Product Portfolio
- 4.6.5 Daiichi Sankyo Company Limited Recent Developments
- 4.7 Astellas Pharma Inc.
- 4.7.1 Astellas Pharma Inc. Company Information
- 4.7.2 Astellas Pharma Inc. Business Overview
- 4.7.3 Astellas Pharma Inc. Urinary Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Astellas Pharma Inc. Urinary Drugs Product Portfolio
- 4.7.5 Astellas Pharma Inc. Recent Developments
- 4.8 Allergan Plc.
- 4.8.1 Allergan Plc. Company Information
- 4.8.2 Allergan Plc. Business Overview
- 4.8.3 Allergan Plc. Urinary Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Allergan Plc. Urinary Drugs Product Portfolio
- 4.8.5 Allergan Plc. Recent Developments
5 Global Urinary Drugs Market Scenario by Region
- 5.1 Global Urinary Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Urinary Drugs Sales by Region: 2021-2032
- 5.2.1 Global Urinary Drugs Sales by Region: 2021-2026
- 5.2.2 Global Urinary Drugs Sales by Region: 2027-2032
- 5.3 Global Urinary Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Urinary Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Urinary Drugs Revenue by Region: 2027-2032
- 5.4 North America Urinary Drugs Market Facts & Figures by Country
- 5.4.1 North America Urinary Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Urinary Drugs Sales by Country (2021-2032)
- 5.4.3 North America Urinary Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Urinary Drugs Market Facts & Figures by Country
- 5.5.1 Europe Urinary Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Urinary Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Urinary Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Urinary Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Urinary Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Urinary Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Urinary Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Urinary Drugs Market Facts & Figures by Country
- 5.7.1 South America Urinary Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Urinary Drugs Sales by Country (2021-2032)
- 5.7.3 South America Urinary Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Urinary Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Urinary Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Urinary Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Urinary Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Urinary Drugs Sales by Type (2021-2032)
- 6.1.1 Global Urinary Drugs Sales by Type (2021-2032) & (k tons)
- 6.1.2 Global Urinary Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Urinary Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Urinary Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Urinary Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Urinary Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Urinary Drugs Sales by Application (2021-2032)
- 7.1.1 Global Urinary Drugs Sales by Application (2021-2032) & (k tons)
- 7.1.2 Global Urinary Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Urinary Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Urinary Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Urinary Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Urinary Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Urinary Drugs Value Chain Analysis
- 8.1.1 Urinary Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Urinary Drugs Production Mode & Process
- 8.2 Urinary Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Urinary Drugs Distributors
- 8.2.3 Urinary Drugs Customers
9 Global Urinary Drugs Analyzing Market Dynamics
- 9.1 Urinary Drugs Industry Trends
- 9.2 Urinary Drugs Industry Drivers
- 9.3 Urinary Drugs Industry Opportunities and Challenges
- 9.4 Urinary Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst